Timing transforms outcomes For people living with severe asthma, outcomes are not determined only by what treatment they receive, but when.1 Evidence now makes one thing clear: delays in care are costing lives, productivity, and public money — and they are largely preventable.2,3,4 In diseases such as cancer, heart failure, and chronic kidney disease, policymakers have long recognised the power of time-bound care pathways.5,6,7 Deadlines for diagnosis, referral, and treatment optimisation are standard practice because they save lives and reduce long-term costs.5,6,7 Severe asthma, affecting an estimated 33.9 million people globally, has yet to benefit from the same urgency.8 That needs to change. A chronic disease still treated as a crisis Despite being a well-characterised condition with clear clinical guidelines, severe asthma is still managed too often as a series of emergencies rather than a disease to be proactively controlled.2 Patients endure years of breathlessness, repeated exacerbations, and frequent emergency department visits before accessing optimal specialist care.2,8 Evidence now makes one thing clear: delays in care are costing lives, productivity, and public money — and they are largely preventable. It acknowledges that severe asthma is not a rare or unpredictable outlier, but a condition where early optimisation can stabilise lung function, reduce exacerbations, and prevent irreversible damage.1,13 Yet in reality, patients can wait more than four years from referral before receiving the treatment that is right for them.14 Those lost years matter.